No title
The prospects for patients suffering from systemic small vessel vasculitis have improved substantially in recent decades. The introduction of cyclophosphamide in the 1970s led to a dramatic improvement in survival rates. The discovery of ANCA meant a substantial increase in the number of detected cases, especially among elderly patients, as well as detection at an earlier stage of disease. At the
